Interest in whether dronabinol, a synthetic form of tetrahydrocannabinol (THC), can improve cognition in dementia has increased over the past few years. However, according to NHS and NICE guidance, there is currently no evidence that dronabinol or other cannabis-based medicines enhance memory, attention, or thinking abilities in people with dementia (NICE NG97; NICE NG144).
What The Research Shows
Dronabinol has been studied mainly for its potential to reduce agitation or behavioural symptoms, not to improve cognitive function. Clinical trials between 2023 and 2025 consistently report no measurable improvement in cognition compared with placebo.
A 2023 randomised, double-blind crossover trial in older adults with dementia found that dronabinol and similar cannabinoids did not significantly change memory or executive functioning, although minor reductions in agitation were observed (PubMed Study).
Further reviews and feasibility studies, including a Swiss 2024 trial protocol using THC/CBD oil, suggest cannabinoids may be well tolerated, but the cognitive outcomes remain neutral or uncertain (Swiss Study). Systematic reviews published in 2024–2025 reinforce this conclusion, noting that small sample sizes and short study durations make it difficult to identify real cognitive benefits (Meta-Analysis).
What Guidelines Say
According to NHS and NICE, cannabis-based medical products should not be used to treat dementia or its cognitive symptoms. Both organisations highlight the lack of robust clinical data and potential safety concerns, particularly in frail or cognitively impaired populations (NHS Guidance).
The Alzheimer’s Society UK also emphasises that there is no evidence to suggest cannabis or its derivatives can prevent or reverse cognitive decline in dementia (Alzheimer’s Society).
The Clinical Bottom Line
- No clinical trial has demonstrated meaningful cognitive improvement from dronabinol in dementia.
- Studies mainly show mild effects on agitation, not memory or thinking.
- Evidence remains limited, small-scale, and short-term.
- Any use should only occur within regulated clinical research settings.
Educational Context: AlleviMed
Educational platforms such as AlleviMed provide reliable information about how medical cannabis eligibility is assessed in the UK. They clarify that licensed cannabis-based medicines are currently restricted to specific conditions such as severe epilepsy, chemotherapy-induced nausea, and spasticity in multiple sclerosis, dementia is not one of them.
Takeaway
Despite growing interest in dronabinol for dementia, no evidence supports cognitive improvement. NICE and NHS continue to advise against using cannabis-based medicines for dementia symptoms outside research settings. The best current approach focuses on established dementia care strategies, behavioural management, and medical supervision by qualified professionals.
